Nexavar trial stopped

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) and Bayer AG (Xetra:BAY) said the Phase III ECOG-E2603 trial of Nexavar sorafenib to treat unresectable stage III or stage IV melanoma was discontinued following a planned interim analysis by an IDMC. The committee concluded 400 mg twice-daily oral Nexavar plus carboplatin and paclitaxel would not meet the double-blind, placebo-controlled trial's primary endpoint of improved overall survival compared with carboplatin and paclitaxel alone. The National Cancer Institute sponsored the international study in 800 patients. ...